一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1300 | 0.1600 | -18.75 | 0.1900 | | 每股净资产（元） | 10.25 | 10.47 | -2.1 | 4.98 | | 每股公积金(元) | 5.96 | 5.95 | 0.17 | 0.41 | | 每股未分配利润(元) | 3.01 | 3.17 | -5.05 | 3.21 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 5.79 | 6.62 | -12.54 | 5.36 | | 净利润(亿元) | 0.19 | 0.22 | -13.64 | 0.2 | | 净资产收益率(%) | 1.31 | 1.51 | -13.25 | 3.86 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 1398.07万股，累计占流通股比： 26.15 ...

Financial Performance - The company reported a basic earnings per share of -0.3268 yuan for 2024, a decrease of 180.71% compared to 0.4049 yuan in 2023 [1] - The net profit for 2024 was -0.33 billion yuan, down 180.49% from 0.41 billion yuan in 2023 [1] - The operating revenue decreased by 14.65% to 8.1 billion yuan in 2024 from 9.49 billion yuan in 2023 [1] - The return on equity was -1.21% in 2024, a significant drop from 1.48% in 2023 [1] - The net asset per share fell to 0 yuan in 2024, a 100% decrease from 27.13 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 10.2495 million shares, accounting for 24.33% of the circulating shares, a decrease of 2.965 million shares from the previous period [1] - Notable shareholders include 尚融宝盈(宁波)投资中心 with 584.52 million shares (13.87%) and 中国银行 with 80 million shares (1.90%), which saw a reduction of 70 million shares [2] - New entrants among the top shareholders include 中国石油天然气集团有限公司企业年金计划 and 中国建设银行, both holding over 49 million shares [2] Dividend Policy - The company has announced no distribution or capital increase for the current period [4]

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 成都展翔投资有限公司 | 676.41 | 8.85 | 不变 | | 严建林 | 560.18 | 7.33 | 不变 | | 栗工 | 384.14 | 5.03 | 不变 | | 许皓 | 155.73 | 2.04 | -23.91 | | 西藏星瑞企业管理服务有限公司 | 110.00 | 1.44 | 新进 | | 韩靓 | 96.41 | 1.26 | 新进 | | 许金林 | 85.05 | 1.11 | -45.18 | | 拉萨鑫宏雅科技有限公司 | 54.60 | 0.71 | 不变 | | 周丽萍 | 52.69 | 0.69 | -0.17 | | 邹丽 | 47.57 | 0.62 | 不变 | | 较上个报告期退出前十大股东有 | | | | | 拉萨市星晴网络科技有限公司 | 125.01 | 1.64 | 退出 | | 招商沪深300指数增强A | 55.07 | 0.72 | 退出 | 三、分红送配方案情况 不 ...

达威股份（300535）公告，2024年营业收入7.53亿元，同比增长3.94%。归属于上市公司股东的净亏损 1144.85万元，去年同期净利润2842.84万元。基本每股收益-0.1092元/股。公司计划不派发现金红利，不 送红股，不以公积金转增股本。 ...

久日新材公告，2024年公司实现营业收入14.88亿元，同比增长20.52%；归属于上市公司股东的净利 润-5376.08万元，较去年同期相比，减少4237.69万元亏损，亏损收窄44.08%。公司2024年度利润分配预 案为：拟不进行利润分配，不派发现金红利，不送红股，不以资本公积金转增股本，剩余未分配利润滚 存至下一年度。 ...

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 26.85 RMB [8][9]. Core Views - The company reported a revenue of 5.3 billion RMB in 2024, remaining stable year-on-year, but the net profit attributable to shareholders decreased by 21% to 560 million RMB [1]. - The decline in net profit is attributed to pressures in the bulk chemical sector and increased unit costs due to the suspension of sucralose production [1]. - The report anticipates a recovery in the sweetener market, supported by supply-side and cost-side factors, which could enhance future profitability [1][3]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 5.3 billion RMB, with a net profit of 560 million RMB, reflecting a year-on-year decrease of 21% [1]. - The fourth quarter of 2024 saw a revenue of 1.26 billion RMB, up 4% year-on-year but down 16% quarter-on-quarter [1]. - The company plans to distribute a cash dividend of 0.83 RMB per share, with a payout ratio of 82% [1]. Market Dynamics - The sweetener prices began to rise in the second half of the previous year due to cost support and supply-side coordination [2]. - The report notes a 14% year-on-year decline in sucralose exports in the first two months of 2025, indicating ongoing market challenges [3]. Project Developments - The company successfully launched several projects, including a 600,000-ton sulfuric acid production facility and an 80,000-ton electronic-grade hydrogen peroxide project, which are expected to contribute to future profits [4]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders is 1.02 billion RMB for 2025, 1.26 billion RMB for 2026, and 1.49 billion RMB for 2027, reflecting growth rates of 83%, 24%, and 18% respectively [5]. - The report assigns a 15x PE ratio for 2025, leading to a target price of 26.85 RMB, which is an increase from the previous target of 25.06 RMB [5].

康鹏科技公告，2025年第一季度营收为2.43亿元，同比增长44.27%；净利润为3062.91万元，同比增长 59.73%。 ...

康鹏科技公告，2024年营业收入6.75亿元，同比下降31.11%。归属于上市公司股东的净利润-4953.16万 元，同比减少143.95%。公司2024年度利润分配预案为不进行利润分配，不进行资本公积金转增股本， 不送红股。 ...

彤程新材（603650）公告，2024年营业收入32.7亿元，同比增长11.10%。归属于上市公司股东的净利润 5.17亿元，同比增长27.10%。公司拟以实施权益分派股权登记日登记的总股本为基数，向全体股东每10 股派发现金红利5元(含税)，拟派发现金红利2.98亿元(含税)。 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown impressive performance due to high prices of vitamins and methionine, with a significant increase in revenue and net profit for 2024 and a strong forecast for Q1 2025 [1][5][8] Summary by Sections Financial Performance - In 2024, the company achieved operating revenue of 21.6 billion yuan, a year-on-year increase of 43%, and a net profit attributable to shareholders of 5.87 billion yuan, up 117% year-on-year. In Q4 alone, the revenue was 5.83 billion yuan, a 42% increase year-on-year, and net profit was 1.88 billion yuan, up 212% year-on-year [4][5] - For Q1 2025, the company expects a net profit of 1.8 to 1.9 billion yuan, representing a year-on-year increase of 107% to 118% [4] Market Conditions - The average price of domestic vitamin A (VA) was 140 yuan/kg in 2024, up 65% year-on-year, and vitamin E (VE) was 102 yuan/kg, up 44% year-on-year. The average price of solid methionine was 21.3 yuan/kg, up 14% year-on-year [5] - In Q1 2025, the average price of VA was 121 yuan/kg, up 47% year-on-year, and VE was 136 yuan/kg, up 107% year-on-year [5] Project Development - The company is progressing steadily with its projects, including a joint venture with Sinopec to build an 18,000-ton/year liquid methionine project and the stable production of 4,000 tons/year of cysteine [6] - The nutrition segment's methionine project has reached a capacity of 300,000 tons/year, enhancing market competitiveness [6] Shareholder Returns - The company has a consistent cash dividend policy, distributing 30%-50% of its net profit as dividends, with a total cash dividend of 15.5 billion yuan since its listing [7] - In 2024, the company repurchased 17,485,676 shares for 500 million yuan and plans to repurchase an additional 300 million to 600 million yuan in 2025 [7] Profit Forecast and Valuation - The report raises profit forecasts for 2025-2026, with net profits expected to be 6.57 billion yuan (up 18%), 7.27 billion yuan (up 15%), and 8.33 billion yuan for 2027 [8] - The estimated EPS for 2025-2027 is projected to be 2.14, 2.36, and 2.71 yuan respectively [8]